Amgen’s muscular disorder drug meets main goal in late-stage study

AMGEN-STUDY/ (UPDATE 3, PIX):UPDATE 3-Amgen's muscular disorder drug meets main goal in late-stage study

Reuters
Published25 Sep 2024, 02:52 AM IST
Amgen's muscular disorder drug meets main goal in late-stage study
Amgen’s muscular disorder drug meets main goal in late-stage study

(Adds background on company's drug uplinza in paragraphs 7-10)

Sept 24 (Reuters) - Amgen said on Tuesday that its drug helped improve daily activities including chewing and swallowing in patients suffering from a rare muscle-weakening disease, meeting the main goal of a late-stage study.

The drug, inebilizumab, was tested in patients suffering from myasthenia gravis, which is caused by an abnormal immune reaction that weakens the muscles that control the eyes, mouth, throat and limbs.

Inebilizumab, also known as uplizna, belongs to a class of drugs that target a protein, called CD19, present on immune cells.

Myasthenia gravis is estimated to affect about 36,000 to 60,000 people in the United States, according to the Myasthenia Gravis Foundation of America.

Separately, the drugmaker also said its experimental drug, rocatinlimab, met the main goals and secondary goals in a late-stage study that tested it as a treatment for an inflammatory skin condition known as atopic dermatitis.

Shares of the drugmaker fell about 2% to $325 in extended trading.

Last year, the U.S. Food and Drug Administration approved Netherlands-based Argenx SE's subcutaneous injection, Vyvgart Hytrulo, as a convenient treatment option for the muscle-weakening condition.

Argenx's drug, which uses the active ingredient efgartigimod, was first approved by the FDA in 2021 as an intravenous injection.

Uplizna is unlikely to meet the high bar set by Argenx's Vyvgart, but its once every 6-months dosing could be a potential differentiator if safety is clean, TD Cowen analyst Yaron Werber said in a note ahead of the results.

Uplizna - if approved for myasthenia gravis - will also compete with AstraZeneca's Soliris, another intravenous treatment.

(Reporting by Mariam Sunny, Bhanvi Satija and Puyaan Singh in Bengaluru; Editing by Alan Barona and Shailesh Kuber)

Catch all the Business News , Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.

MoreLess
First Published:25 Sep 2024, 02:52 AM IST
Business NewsNewsAmgen’s muscular disorder drug meets main goal in late-stage study

Get Instant Loan up to ₹10 Lakh!

  • Employment Type

    Most Active Stocks

    Tata Steel share price

    138.65
    01:15 PM | 14 NOV 2024
    -0.6 (-0.43%)

    Indian Oil Corporation share price

    135.85
    01:15 PM | 14 NOV 2024
    -0.15 (-0.11%)

    Tata Motors share price

    777.70
    01:15 PM | 14 NOV 2024
    -8.7 (-1.11%)

    Bharat Electronics share price

    283.30
    01:15 PM | 14 NOV 2024
    1.85 (0.66%)
    More Active Stocks

    Market Snapshot

    • Top Gainers
    • Top Losers
    • 52 Week High

    HCL Technologies share price

    1,854.60
    01:05 PM | 14 NOV 2024
    -9.85 (-0.53%)
    More from 52 Week High

    SKF India share price

    4,608.30
    12:59 PM | 14 NOV 2024
    -263.65 (-5.41%)

    P I Industries share price

    4,226.30
    01:05 PM | 14 NOV 2024
    -222.8 (-5.01%)

    Astrazeneca Pharma India share price

    6,800.05
    01:05 PM | 14 NOV 2024
    -333.05 (-4.67%)

    ITI share price

    282.85
    01:06 PM | 14 NOV 2024
    -9.65 (-3.3%)
    More from Top Losers

    Eicher Motors share price

    4,940.30
    01:06 PM | 14 NOV 2024
    351.2 (7.65%)

    Deepak Fertilisers & Petrochemicals Corporation share price

    1,324.00
    01:06 PM | 14 NOV 2024
    87 (7.03%)

    Network 18 Media & Investments share price

    82.66
    01:06 PM | 14 NOV 2024
    4.51 (5.77%)

    DCM Shriram share price

    1,254.35
    01:04 PM | 14 NOV 2024
    67.5 (5.69%)
    More from Top Gainers

    Recommended For You

      More Recommendations

      Gold Prices

      • 24K
      • 22K
      Bangalore
      76,855.00-10.00
      Chennai
      76,861.00-10.00
      Delhi
      77,013.00-10.00
      Kolkata
      76,865.00-10.00

      Fuel Price

      • Petrol
      • Diesel
      Bangalore
      102.92/L-0.10
      Chennai
      100.80/L-0.10
      Kolkata
      104.95/L0.00
      New Delhi
      94.77/L0.00

      Popular in News

        HomeMarketsPremiumInstant LoanMint Shorts